middle.news
Immutep finds new footing after TACTI-004 setback
1:28pm on Tuesday 27th of October, 2026 AEDT
•
Biotechnology
Read Story
Immutep finds new footing after TACTI-004 setback
1:28pm on Tuesday 27th of October, 2026 AEDT
Key Points
TACTI-004 discontinued after an interim futility analysis involving about 170 patients
FY26 net loss widened to A$79.3 million from A$61.4 million
Cash, cash equivalents and term deposits stood at A$68.9 million
Management forecasts funding into the first half of CY2028 under current plans
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE